Ignite Creation Date:
2024-05-06 @ 8:00 AM
Last Modification Date:
2024-10-26 @ 11:55 AM
Study NCT ID:
NCT02648477
Status:
COMPLETED
Last Update Posted:
2024-03-19
First Post:
2016-01-05
Brief Title:
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
Sponsor:
City of Hope Medical Center
Organization:
City of Hope Medical Center
Organization Data
Organization:
City of Hope Medical Center
Class:
OTHER
Study ID:
15295
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
City of Hope Medical Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Merck Sharp Dohme LLC | INDUSTRY |
| National Cancer Institute NCI | NIH |